Record NNP B-NP O
date NN I-NP O
: : O O
2062-08-30 CD O B-DATE
CCU NNP B-NP O
JAR NNP I-NP O
Admit NNP I-NP O
Note NN I-NP O
Name NN B-NP O
: : O O
Jacob NNP B-NP B-PATIENT
Goins NNP I-NP I-PATIENT
MR NNP B-NP O
# # I-NP O
: : O O
6850327 CD B-NP B-MEDICALRECORD
( -LRB- I-NP O
Please VB I-NP O
note NN I-NP O
that IN B-PP O
pt NN B-NP O
also RB B-ADVP O
has VBZ B-VP O
MRN JJ B-NP O
4033790 CD I-NP B-MEDICALRECORD
) -RRB- O O
Date NNP B-NP O
of IN B-PP O
admission NN B-NP O
: : O O
8/30/2062 CD O B-DATE
Resident NN B-NP O
: : O O
Addison NNP B-NP B-DOCTOR
Keefe NNP I-NP I-DOCTOR
Attending VBG B-VP O
: : O O
Angel NNP B-NP B-DOCTOR
Vail NNP I-NP I-DOCTOR
PCP NNP B-NP O
: : O O
Felicia NNP B-NP B-DOCTOR
Ali NNP I-NP I-DOCTOR
Source NN B-NP O
: : O O
Medical NNP B-NP O
Record NNP I-NP O
and CC O O
Family NNP B-NP O
CC NNP B-NP O
: : O O
L NNP B-NP O
Arm NNP I-NP O
Weakness . O O
HPI NNP B-NP O
: : O O
28 CD B-NP B-AGE
yo NNP I-NP O
RH NNP I-NP O
M NNP I-NP O
h/o , O O
DM1 NNP B-NP O
, , O O
ESRD NNP B-NP O
on IN B-PP O
HD NNP B-NP O
, , O O
HTN NNP B-NP O
, , O O
Stroke NNP B-NP O
( -LRB- I-NP O
thought VBD B-VP O
to TO I-VP O
be VB I-VP O
due JJ B-ADJP O
to TO B-PP O
thrombocytosis NN B-NP O
) -RRB- I-NP O
, , O O
GTC NNP B-NP O
in IN B-PP O
setting VBG B-VP O
of IN B-PP O
HTN NNP B-NP O
one CD I-NP O
year NN I-NP O
ago IN B-PP O
( -LRB- B-NP O
and CC B-PP O
in IN B-PP O
June NNP B-NP B-DATE
per IN B-PP O
family NN B-NP O
) -RRB- I-NP O
, , O O
multiple JJ B-NP O
HTN NNP I-NP O
episodes NNS I-NP O
on IN B-PP O
many JJ B-NP O
anti-hypertensives NNS I-NP O
, , O O
RIJ NNP B-NP O
thrombosis NN I-NP O
, , O O
had VBD B-VP O
transient JJ B-NP O
L NNP I-NP O
arm NN I-NP O
weakness NN I-NP O
at IN B-PP O
HD NNP B-NP O
followed VBD B-VP O
by IN B-PP O
some DT B-NP O
difficulty NN I-NP O
speaking VBG B-VP O
and CC I-VP O
change VB I-VP O
in IN B-PP O
his PRP$ B-NP O
mental JJ I-NP O
status NN I-NP O
. . O O
He PRP B-NP O
was VBD B-VP O
reportedly RB B-ADVP O
in IN B-PP O
good JJ B-NP O
health NN I-NP O
the DT B-NP O
night NN I-NP O
prior RB B-ADVP O
to TO B-PP O
admission NN B-NP O
and CC O O
the DT B-NP O
morning NN I-NP O
of IN B-PP O
admission NN B-NP O
per IN B-PP O
his PRP$ B-NP O
family NN I-NP O
, , O O
with IN B-PP O
no DT B-NP O
sick JJ I-NP O
contacts NNS I-NP O
and CC O O
no DT B-NP O
travel NN I-NP O
. . O O
At IN B-PP O
HD NNP B-NP O
he PRP B-NP O
was VBD B-VP O
hypertensive JJ B-ADJP O
with IN B-PP O
SBP NNP B-NP O
in IN B-PP O
200s CD B-NP O
, , O O
had VBD B-VP O
transient JJ B-NP O
L NNP I-NP O
arm NN I-NP O
weakness NN I-NP O
and CC I-NP O
paresthesias NNS I-NP O
which WDT B-NP O
then RB B-ADVP O
resolved VBD B-VP O
and CC O O
had VBD B-VP O
difficulty NN B-NP O
speaking VBG B-VP O
and CC I-VP O
following VBG I-VP O
commands NNS B-NP O
after IN B-PP O
being VBG B-VP O
noted VBN I-VP O
by IN B-PP O
his PRP$ B-NP O
nephrologist NN I-NP O
at IN B-PP O
an DT B-NP O
OSH NNP I-NP O
to TO B-VP O
be VB I-VP O
mentating VBG I-VP O
well RB B-ADVP O
with IN B-PP O
normal JJ B-NP O
speech NN I-NP O
. . O O
No DT B-NP O
urinary/bowel NN I-NP O
incontinence NN I-NP O
, , O O
tonic-clonic JJ B-NP O
movements NNS I-NP O
or CC I-NP O
syncope NN I-NP O
was VBD B-VP O
noted VBN I-VP O
by IN B-PP O
his PRP$ B-NP O
providers NNS I-NP O
. . O O
He PRP B-NP O
was VBD B-VP O
brought VBN I-VP O
to TO B-PP O
BMH NNP B-NP B-HOSPITAL
ED NNP I-NP O
because IN B-PP O
of IN I-PP O
these DT B-NP O
problems NNS I-NP O
. . O O
In IN B-PP O
the DT B-NP O
ED NNP I-NP O
, , O O
his PRP$ B-NP O
initial JJ I-NP O
VS NNP I-NP O
were VBD B-VP O
BP NNP B-NP O
211/120 CD I-NP O
HR NNP I-NP O
88 CD I-NP O
T NNP I-NP O
98 CD I-NP O
R NN I-NP O
18 CD I-NP O
SaO2 NNP I-NP O
100 CD I-NP O
% NN I-NP O
RA. NN I-NP O
he PRP B-NP O
received VBD B-VP O
a DT B-NP O
Head NN I-NP O
CT NN I-NP O
which WDT B-NP O
showed VBD B-VP O
no DT B-NP O
acute JJ I-NP O
infarct NN I-NP O
or CC O O
ICH NNP B-NP O
, , O O
an DT B-NP O
MRI NNP I-NP O
which WDT B-NP O
showed VBD B-VP O
no DT B-NP O
acute JJ I-NP O
infarct NN I-NP O
on IN B-PP O
DWI NNP B-NP O
, , O O
but CC O O
he PRP B-NP O
was VBD B-VP O
agitated VBN I-VP O
in IN B-PP O
the DT B-NP O
scanner NN I-NP O
and CC O O
could MD B-VP O
not RB I-VP O
complete VB I-VP O
the DT B-NP O
study NN I-NP O
. . O O
He PRP B-NP O
received VBD B-VP O
5 CD B-NP O
mg NN I-NP O
hydralazine NN I-NP O
iv NN I-NP O
x NN I-NP O
2 CD B-NP O
and CC O O
was VBD B-VP O
started VBN I-VP O
first RB B-ADVP O
in IN B-PP O
a DT B-NP O
TNG NNP I-NP O
gtt NN I-NP O
and CC O O
then RB B-ADVP O
on IN B-PP O
a DT B-NP O
nitroprusside NN I-NP O
gtt NN I-NP O
to TO B-PP O
100/min CD B-NP O
titrated VBN I-NP O
to TO B-PP O
a DT B-NP O
goal NN I-NP O
of IN B-PP O
MAP NNP B-NP O
120 CD I-NP O
. . O O
His PRP$ B-NP O
BP NNP I-NP O
was VBD B-VP O
251/104 CD B-NP O
at IN B-PP O
2315 CD B-NP O
. . O O
and CC O O
was VBD B-VP O
His PRP$ B-NP O
L NNP I-NP O
Arm NN I-NP O
Weakness NNP I-NP O
resolved VBD B-VP O
, , O O
but CC O O
he PRP B-NP O
was VBD B-VP O
agitated VBN I-VP O
and CC O O
he PRP B-NP O
transiently RB B-ADVP O
wanted VBD B-VP O
to TO I-VP O
leave VB I-VP O
AMA NNP B-NP O
, , O O
and CC O O
was VBD B-VP O
admitted VBN I-VP O
to TO B-PP O
the DT B-NP O
CCU NNP I-NP O
for IN B-PP O
further JJ B-NP O
management NN I-NP O
. . O O
ROS NNP B-NP O
: : O O
Per IN B-SBAR O
HPI. NNP B-NP O
Other JJ I-NP O
systems NNS I-NP O
negative JJ B-ADJP O
in IN B-PP O
detail NN B-NP O
PMH: . O O
a DT B-NP O
. . O O
Thrombocytosis '' O O
1 LS O O
. . O O
Followed NNP O O
by IN B-PP O
Dr. NNP B-NP O
Morgan NNP I-NP B-DOCTOR
at IN B-PP O
BMH NNP B-NP B-HOSPITAL
1 CD B-LST O
. . O O
-ve -RRB- B-VP O
JAK2 NNP B-NP O
mutation NN I-NP O
and CC O O
-ve JJ B-NP O
myeloproliferative JJ I-NP O
w/u NN I-NP O
2. DT B-NP O
Had VBD B-VP O
high JJ B-NP O
ferritin NN I-NP O
, , O O
low JJ B-NP O
TIBC NNP I-NP O
and CC I-NP O
high JJ I-NP O
ESR NN I-NP O
levels NNS I-NP O
when WRB B-ADVP O
checked VBN B-VP O
in IN B-PP O
the DT B-NP O
past NN I-NP O
. . O O
3. . B-NP O
On IN B-PP O
Hydrea NNP B-NP O
b NN B-NP O
. . O O
ESRD NNP O O
due JJ B-ADJP O
to TO B-PP O
DM1 NNP B-NP O
and CC I-NP O
HTN NNP I-NP O
1 CD B-NP O
. . O O
Biopsy NNP O O
( -LRB- O O
3/62 NN B-NP B-DATE
) -RRB- B-VP O
with IN B-PP O
advanced JJ B-NP O
diabetic JJ I-NP O
glomerulopathy NN I-NP O
and CC O O
secondary JJ B-NP O
FSGS NNS I-NP O
2. VBG B-NP O
Had VBD B-VP O
R NN B-NP O
AVG NN I-NP O
( -LRB- O O
7/04 CD B-NP B-DATE
) -RRB- I-NP O
, , O O
now RB B-ADVP O
on IN B-PP O
HD NNP B-NP O
x NN I-NP O
1 CD B-NP O
month NN I-NP O
3/wk NN I-NP O
. . O O
3. . B-NP O
Being VBG B-VP O
evaluated VBN I-VP O
for IN B-PP O
transplant NN B-NP O
c. NN B-NP O
DM1 NNP I-NP O
since IN B-PP O
age NN B-NP O
11 CD I-NP B-AGE
1 LS O O
. . O O
HgbA1C VB B-VP O
7.6 CD B-NP O
% NN I-NP O
in IN B-PP O
7/62 CD B-NP B-DATE
2. DT B-NP O
Repeated VBN I-NP O
hypoglycemic JJ I-NP O
episodes NNS I-NP O
in IN B-PP O
the DT B-NP O
past NN I-NP O
3. DT B-NP O
Hx NNP I-NP O
of IN B-PP O
DKA NNP B-NP O
d NN B-NP O
. . O O
HTN NNP B-NP O
has VBZ B-VP O
had VBN I-VP O
e NN B-NP O
. . O O
Hyperlipidemia NN O O
f NN B-NP O
. . O O
Anemia '' O O
g VBG B-VP O
. . O O
GTC NNP O O
in IN B-PP O
August NNP B-NP B-DATE
last JJ B-NP O
year NN I-NP O
and CC O O
per IN B-PP O
family NN B-NP O
report NN I-NP O
, , O O
in IN B-PP O
June NNP B-NP B-DATE
of IN B-PP O
this DT B-NP O
year NN I-NP O
- : O O
attributed VBN B-VP O
to TO B-PP O
HTN. NNP B-NP O
Was VBD B-VP O
briefly RB B-ADVP O
on IN B-PP O
dilantin NN B-NP O
, , O O
but CC O O
this DT B-NP O
was VBD B-VP O
d/c JJ B-NP O
'd NNP I-NP O
due JJ I-NP O
to TO B-PP O
side NN B-NP O
effects NNS I-NP O
. . O O
h NN B-NP O
. . O O
MRI '' O O
with IN B-PP O
embolic JJ B-NP O
foci NNS I-NP O
in IN B-PP O
August NNP B-NP B-DATE
2061 CD I-NP I-DATE
1 LS B-NP O
. . O O
w/u RB B-ADVP O
proved VBD B-VP O
negative JJ B-ADJP O
- : O O
attributed VBN B-VP O
to TO B-PP O
thrombophilia NNS B-NP O
Medications NNS B-NP O
on IN B-PP O
admission NN B-NP O
: : O O
aspirin NN B-NP O
81mg CD I-NP O
po NN I-NP O
qd NN I-NP O
clonidine NN B-NP O
0.3mg CD I-NP O
po NN I-NP O
1 CD I-NP O
tabs NN I-NP O
po NN I-NP O
q NN I-NP O
pm NN I-NP O
Diovan NNP B-NP O
320mg CD I-NP O
po NN I-NP O
qd NN I-NP O
furosemide JJ B-NP O
20 CD I-NP O
mg NN I-NP O
po NN I-NP O
qd . O O
Humulin NNP B-NP O
n RB I-NP O
35 CD I-NP O
units NNS I-NP O
qam VBP B-VP O
sc NN B-NP O
25 CD B-NP O
units NNS I-NP O
qpm . O O
Hydrea NNP B-NP O
500mg CD I-NP O
po NN I-NP O
bid NN I-NP O
Insulin NNP B-NP O
syringes NNS I-NP O
(u VBD B-VP O
100 CD B-NP O
) -RRB- O O
labetalol NN B-NP O
hcl NN I-NP O
tablets NNS B-VP O
600 CD B-NP O
mg JJ I-NP O
po NN I-NP O
bid NN I-NP O
Lancets NNS B-NP O
Lipitor NNP B-NP O
40mg CD I-NP O
po NN I-NP O
qd NN I-NP O
lisinopril NN B-NP O
40mg CD I-NP O
po NN I-NP O
qd NN I-NP O
Nephrocaps NNP B-NP O
1 CD I-NP O
po NN I-NP O
q NN I-NP O
d CC O O
Nexium NNP B-NP O
40mg CD I-NP O
po NN I-NP O
bid NN I-NP O
nifedipine JJ B-NP O
xl JJ I-NP O
90mg JJ I-NP O
sr NN I-NP O
po NN I-NP O
qhs NNS I-NP O
Onetouch DT B-NP O
test NN I-NP O
strips NNS I-NP O
potassium NN B-NP O
chloride NN I-NP O
10meq IN B-PP O
po NN B-NP O
qd CC O O
regular JJ B-NP O
insulin NN I-NP O
25 CD B-NP O
units NNS I-NP O
qam IN B-PP O
sc NN B-NP O
20 CD B-NP O
units NNS I-NP O
qpm . O O
ALL NNP B-NP O
: : O O
NKDA NNP O O
SH NNS B-NP O
: : O O
Lives NNS B-NP O
with IN B-PP O
: : O O
Mother NNP B-NP O
. . I-NP O
Used NNP I-NP O
to TO B-VP O
work VB I-VP O
at IN B-PP O
Bebo NNP B-NP B-ORGANIZATION
in IN B-PP O
Geologist NNP B-NP B-PROFESSION
, , O O
currently RB B-VP O
unemployed VBN I-VP O
. . O O
No DT B-NP O
EtOH NNP I-NP O
, , I-NP O
Illicits NNP I-NP O
, , I-NP O
Tobacco NNP I-NP O
. . O O
FH NNP B-NP O
: : O O
HTN NNP B-VP O
in IN B-PP O
parents NNS B-NP O
, , O O
Mother NNP B-NP O
with IN B-PP O
Stroke NNP B-NP O
, , O O
Father NNP B-NP O
on IN B-PP O
HD NNP B-NP O
, , O O
DM1 NNP B-NP O
, , O O
DM2 NNP B-NP O
, , O O
CKD NNP B-NP O
in IN B-PP O
other JJ B-NP O
family NN I-NP O
members NNS I-NP O
. . O O
Physical JJ B-NP O
Exam NNP I-NP O
: : O O
V NNP B-NP O
: : O O
T NNP B-NP O
99.9 CD I-NP O
BP NNP I-NP O
210/90 CD I-NP O
P NNP I-NP O
110 CD I-NP O
R NN I-NP O
20 CD I-NP O
SaO2 NNP I-NP O
100 CD I-NP O
% NN I-NP O
RA NN I-NP O
Gen NNP B-NP O
: : O O
WDWN NNP B-NP O
American NNP I-NP O
male JJ I-NP O
following JJ I-NP O
commands NNS I-NP O
intermittently RB B-ADVP O
. . O O
HEENT NNP B-NP O
: : O O
NCAT NNP B-NP O
, , O O
PERRL NNP B-NP O
, , O O
EOMF NNP B-NP O
, , O O
sclera NN B-NP O
anicteric NN I-NP O
. . O O
Neck NNP B-NP O
: : O O
Supple NNP B-NP O
, , O O
no DT B-NP O
thyromegaly NN I-NP O
, , O O
no DT B-NP O
carotid NN I-NP O
bruits NNS I-NP O
, , O O
JVP NNP B-NP O
flat NN I-NP O
Nodes NNP B-NP O
: : O O
No DT B-NP O
cervical JJ I-NP O
or CC I-NP O
supraclavicular JJ I-NP O
LAN . O O
Cor NNP B-NP O
: : O O
Tachy NNP B-NP O
, , O O
RR NNP B-NP O
S1 NNP I-NP O
, , O O
S2 NNP B-NP O
nl , O O
. . O O
No DT B-NP O
m/r/g NN I-NP O
. . B-PP O
+ DT B-NP O
S3 NNPS I-NP O
, , O O
prominent JJ B-NP O
PMI NNP I-NP O
. . O O
Chest NNP B-NP O
: : O O
CTAB NNP B-NP O
anteriorly CC O O
Abdomen NNP B-NP O
: : O O
+BS NNP B-NP O
Soft NNP I-NP O
, , O O
NT NNP B-NP O
, , O O
ND. NNP B-NP O
No NNP I-NP O
HSM NNP I-NP O
, , O O
No DT B-NP O
CVA NNP I-NP O
tenderness NN I-NP O
. . O O
L NNP B-NP O
para-umbilical JJ I-NP O
bruit NN I-NP O
, , O O
no DT B-NP O
pulsatile JJ I-NP O
mass NN I-NP O
. . O O
Ext NNP B-NP O
: : O O
No DT B-NP O
C/C/E NN I-NP O
, , O O
warm JJ B-NP O
, , I-NP O
well-perfused JJ I-NP O
, , I-NP O
subcutaneous JJ I-NP O
mass NN I-NP O
on IN B-PP O
anterior NN B-NP O
R NN I-NP O
thigh NN I-NP O
, , O O
R NN B-NP O
AV NN I-NP O
fistula NN I-NP O
with IN B-PP O
thrill NN B-NP O
. . O O
3+ CD B-NP O
DP NNP I-NP O
and CC I-NP O
PT NNP I-NP O
pulses NNS I-NP O
b.l RB B-ADVP O
. . O O
Has VBZ B-VP O
indwelling VBG I-VP O
L NNP B-NP O
arterial NN I-NP O
line NN I-NP O
. . O O
Skin NNP B-NP O
: : O O
No DT B-NP O
rashes NNS I-NP O
. . O O
Neuro NNP B-NP O
: : O O
A DT B-NP O
, , O O
O UH B-NP O
x NN I-NP O
1 CD I-NP O
, , O O
PERRL NNP B-NP O
, , O O
EOMF NNP B-NP O
, , O O
Smile NNP B-NP O
symmetric JJ I-NP O
, , O O
Sensation NNP B-NP O
grossly RB I-NP O
intact JJ I-NP O
to TO B-PP O
light JJ B-NP O
touch NN I-NP O
, , O O
Strength NNP B-NP O
5/5 CD I-NP O
in IN B-PP O
flexion NN B-NP O
and CC I-NP O
extension NN I-NP O
in IN B-PP O
upper JJ B-NP O
and CC I-NP O
lower JJR I-NP O
extremities NNS I-NP O
. . O O
Reflexes NNP B-NP O
2+ VBD B-VP O
, , O O
toes NNS B-NP O
downgoing NN I-NP O
. . O O
Labs NNS B-NP O
and CC I-NP O
Studies NNS I-NP O
: : O O
Chemistry NN B-NP O
Lytes/Renal/Glucose NN B-NP O
Sodium NNP B-NP O
136 CD I-NP O
135-145 CD I-NP O
mmol/L NN I-NP O
08/29/62 NN I-NP B-DATE
17 CD B-NP O
:13 CD I-NP O
Potassium NNP B-NP O
3.5 CD I-NP O
3.4-4.8 CD I-NP O
mmol/L NN I-NP O
08/29/62 NN I-NP B-DATE
17 CD B-NP O
:13 CD I-NP O
Chloride NNP B-NP O
99L NNP I-NP O
100-108 CD I-NP O
mmol/L NN I-NP O
08/29/62 NN I-NP B-DATE
17 CD I-NP O
:13 CD I-NP O
99( JJ I-NP O
L NNP I-NP O
) -RRB- I-NP O
08/29/62 CD I-NP B-DATE
17 CD I-NP O
:13 . O O
Carbon NNP B-NP O
Dioxide NNP I-NP O
30.6 CD I-NP O
23.0-31.9 CD I-NP O
mmol/L NN I-NP O
08/29/62 NN I-NP B-DATE
17 CD B-NP O
:13 CD I-NP O
BUN NNP B-NP O
24 CD I-NP O
8-25 CD I-NP O
mg/dl JJ I-NP O
08/29/62 NN I-NP B-DATE
17 CD I-NP O
:13 CD O O
Creatinine NNP B-NP O
5.0H CD I-NP O
0.6-1.5 CD I-NP O
mg/dl NN I-NP O
08/29/62 CD I-NP B-DATE
17 CD I-NP O
:13 NN I-NP O
5.0( CD I-NP O
H) NNP I-NP O
08/29/62 CD I-NP B-DATE
17 CD I-NP O
:13 . O O
Glucose DT B-NP O
91 CD I-NP O
70-110 CD I-NP O
mg/dl NN I-NP O
08/29/62 NN I-NP B-DATE
17 CD B-NP O
:13 CD I-NP O
General NNP B-NP O
Chemistries NNPS I-NP O
Bilirubin NNP B-NP O
( -LRB- I-NP O
To... NNP I-NP O
0.8 CD I-NP O
0.0-1.0 CD I-NP O
mg/dl JJ I-NP O
08/29/62 NN I-NP B-DATE
17 CD I-NP O
:45 CD O O
Bilirubin NNP B-NP O
( -LRB- I-NP O
Di NNP I-NP O
... : O O
0.3 CD B-NP O
0-0.4 CD I-NP O
mg/dl JJ I-NP O
08/29/62 NN I-NP B-DATE
17 CD I-NP O
:45 CD O O
Total JJ B-NP O
Protein NNP I-NP O
8.0 CD I-NP O
6.0-8.3 CD I-NP O
g/dl JJ I-NP O
08/29/62 NN I-NP B-DATE
17 CD I-NP O
:45 CD O O
Albumin NNP B-NP O
3.8 CD I-NP O
3.3-5.0 CD I-NP O
g/dl NN I-NP O
08/29/62 NN I-NP B-DATE
17 CD B-NP O
:45 CD I-NP O
Globulin NNP B-NP O
4.2H CD I-NP O
2.6-4.1 CD I-NP O
g/dl JJ I-NP O
08/29/62 NN I-NP B-DATE
17 CD I-NP O
:45 CD I-NP O
4.2( JJ I-NP O
H) NNP I-NP O
08/29/62 CD I-NP B-DATE
17 CD I-NP O
:45 . O O
Liver NN B-NP O
Function NNP I-NP O
Tests . O O
ALT JJ B-NP O
(SGPT NN I-NP O
) -RRB- I-NP O
11 CD I-NP O
10-55 CD I-NP O
U/L NNP I-NP O
08/29/62 CD I-NP B-DATE
17 CD I-NP O
:45 . O O
AST NN B-NP O
(SGOT NN I-NP O
) -RRB- I-NP O
29 CD I-NP O
10-40 CD I-NP O
U/L NNP I-NP O
08/29/62 CD I-NP B-DATE
17 CD I-NP O
:45 . O O
Alk NNP B-NP O
Phos NNP I-NP O
76 CD I-NP O
45-115 CD I-NP O
U/L NNP I-NP O
08/29/62 CD I-NP B-DATE
17 CD I-NP O
:45 . O O
Bilirubin NNP B-NP O
( -LRB- I-NP O
To... NNP I-NP O
0.8 CD I-NP O
0.0-1.0 CD I-NP O
mg/dl JJ I-NP O
08/29/62 NN I-NP B-DATE
17 CD I-NP O
:45 CD O O
Bilirubin NNP B-NP O
( -LRB- I-NP O
Di NNP I-NP O
... : O O
0.3 CD B-NP O
0-0.4 CD I-NP O
mg/dl JJ I-NP O
08/29/62 NN I-NP B-DATE
17 CD I-NP O
:45 CD O O
Hematology NNP B-NP O
Complete JJ B-NP O
Blood NN I-NP O
Count NN I-NP O
WBC NNP B-NP O
14.9H CD I-NP O
4.5-11.0 CD I-NP O
th/cmm IN B-PP O
08/29/62 CD B-NP B-DATE
17 CD I-NP O
:12 NN I-NP O
14.9( CD I-NP O
H) NNP I-NP O
08/29/62 CD I-NP B-DATE
17 CD I-NP O
:12 . O O
RBC NNP B-NP O
3.88L CD I-NP O
4.50-5.90 CD I-NP O
mil/cm NN I-NP O
08/29/62 NN I-NP B-DATE
17 CD I-NP O
:12 CD I-NP O
3.88( JJ I-NP O
L NNP I-NP O
) -RRB- I-NP O
08/29/62 CD I-NP B-DATE
17 CD I-NP O
:12 . O O
Hgb NNP B-NP O
14.3 CD I-NP O
13.5-17.5 CD I-NP O
gm/dl JJ I-NP O
08/29/62 NN I-NP B-DATE
17 CD I-NP O
:12 CD O O
HCT NNP B-NP O
41.2 CD I-NP O
41.0-53.0 CD I-NP O
% NN I-NP O
08/29/62 NN I-NP B-DATE
17 CD I-NP O
:12 CD O O
MCV NNP B-NP O
106H CD I-NP O
80-100 CD I-NP O
fl NN I-NP O
08/29/62 CD I-NP B-DATE
17 CD I-NP O
:12 NN I-NP O
106( CD I-NP O
H) NNP I-NP O
08/29/62 CD I-NP B-DATE
17 CD I-NP O
:12 . O O
MCH NNP B-NP O
36.8H CD I-NP O
26.0-34.0 CD I-NP O
pg/rbc NN I-NP O
08/29/62 CD I-NP B-DATE
17 CD I-NP O
:12 NN I-NP O
36.8( CD I-NP O
H) NNP I-NP O
08/29/62 CD I-NP B-DATE
17 CD I-NP O
:12 . O O
MCHC NNP B-NP O
34.7 CD I-NP O
31.0-37.0 CD I-NP O
g/dl JJ I-NP O
08/29/62 NN I-NP B-DATE
17 CD I-NP O
:12 CD O O
PLT NNP B-NP O
839H CD I-NP O
150-350 CD I-NP O
th/cumm IN B-PP O
08/29/62 CD B-NP B-DATE
17 CD I-NP O
:12 NN I-NP O
839( CD I-NP O
H) NNP I-NP O
08/29/62 CD I-NP B-DATE
17 CD I-NP O
:12 . O O
RDW NNP B-NP O
17.1H CD I-NP O
11.5-14.5 CD I-NP O
% NN I-NP O
08/29/62 CD I-NP B-DATE
17 CD I-NP O
:12 NN I-NP O
17.1( CD I-NP O
H) NNP I-NP O
08/29/62 CD I-NP B-DATE
17 CD I-NP O
:12 . O O
Blood NN B-NP O
Differential NNP I-NP O
% NN I-NP O
Differential JJ B-NP O
... : O O
RECEIVED VBN B-VP O
08/29/62 NN B-NP B-DATE
17 CD I-NP O
:09 CD O O
Diff JJ B-NP O
Method NNP I-NP O
Auto NNP I-NP O
08/29/62 NNP I-NP B-DATE
17 CD I-NP O
:13 CD O O
Neutrophils NNS B-NP O
88H IN B-PP O
40-70 CD B-NP O
% NN I-NP O
08/29/62 NN I-NP B-DATE
17 CD I-NP O
:13 CD I-NP O
88( IN B-PP O
H) NNP B-NP O
08/29/62 CD I-NP B-DATE
17 CD I-NP O
:13 . O O
Lymphs NNS B-NP O
8L JJ I-NP O
22-44 CD I-NP O
% NN I-NP O
08/29/62 NN I-NP B-DATE
17 CD I-NP O
:13 CD I-NP O
8( JJ I-NP O
L NNP I-NP O
) -RRB- I-NP O
08/29/62 VBP B-VP B-DATE
17 CD B-NP O
:13 CD I-NP O
Monos NNP B-NP O
3L IN I-NP O
4-11 CD I-NP O
% NN I-NP O
08/29/62 NN I-NP B-DATE
17 CD I-NP O
:13 CD I-NP O
3( JJ I-NP O
L NNP I-NP O
) -RRB- I-NP O
08/29/62 VBP B-VP B-DATE
17 CD B-NP O
:13 CD I-NP O
Eos NNS B-NP O
1 CD B-NP O
0-8 CD I-NP O
% NN I-NP O
08/29/62 NN I-NP B-DATE
17 CD I-NP O
:13 CD O O
Basos NNS B-NP O
0 CD B-NP O
0-3 CD I-NP O
% NN I-NP O
08/29/62 NN I-NP B-DATE
17 CD I-NP O
:13 CD O O
Blood NN B-NP O
Diff JJ I-NP O
- : O O
Absolute JJ O O
Neutrophil NNP B-NP O
# # I-NP O
13.14H CD I-NP O
1.8-7.7 CD I-NP O
th/cmm IN B-PP O
08/29/62 CD B-NP B-DATE
17 CD I-NP O
:13 NN I-NP O
13.14( CD I-NP O
H) NNP I-NP O
08/29/62 CD I-NP B-DATE
17 CD I-NP O
:13 . O O
Lymph# NNP B-NP O
1.16 CD I-NP O
1.0-4.8 CD I-NP O
th/cmm JJ I-NP O
08/29/62 NN I-NP B-DATE
17 CD I-NP O
:13 CD O O
Mono# NNP B-NP O
0.45H CD I-NP O
0.2-0.4 CD I-NP O
th/cmm IN B-PP O
08/29/62 CD B-NP B-DATE
17 CD I-NP O
:13 NN I-NP O
0.45( CD I-NP O
H) NNP I-NP O
08/29/62 CD I-NP B-DATE
17 CD I-NP O
:13 . O O
Eos# NNP B-NP O
0.09L CD I-NP O
0.1-0.3 CD I-NP O
th/cmm IN B-PP O
08/29/62 CD B-NP B-DATE
17 CD I-NP O
:13 CD I-NP O
0.09( JJ I-NP O
L NNP I-NP O
) -RRB- I-NP O
08/29/62 CD I-NP B-DATE
17 CD I-NP O
:13 . O O
Baso# NNP B-NP O
0.03 CD I-NP O
0.0-0.3 CD I-NP O
th/cmm IN B-PP O
08/29/62 CD B-NP B-DATE
17 CD I-NP O
:13 . O O
Smear NNP B-NP O
Morphology NNP I-NP O
Anisocytosis NNP B-NP O
1+H NNP I-NP O
None NN I-NP O
08/29/62 NN I-NP B-DATE
17 CD I-NP O
:13 CD I-NP O
1+( IN B-PP O
H) NNP B-NP O
08/29/62 CD I-NP B-DATE
17 CD I-NP O
:13 . O O
Hypochromia NNP B-NP O
None NN I-NP O
None NN I-NP O
08/29/62 IN B-PP B-DATE
17 CD B-NP O
:13 CD I-NP O
Macrocytes NNP B-NP O
3+H NNP I-NP O
None NN I-NP O
08/29/62 IN B-PP B-DATE
17 CD B-NP O
:13 CD I-NP O
3+( IN B-PP O
H) NNP B-NP O
08/29/62 CD I-NP B-DATE
17 CD I-NP O
:13 . O O
Microcytes NNS B-NP O
None NN I-NP O
None NN I-NP O
08/29/62 NN B-VP B-DATE
17 CD B-NP O
:13 CD I-NP O
Coagulation NN B-NP O
Routine NNP B-NP O
Coagulation NNP I-NP O
PT NNP B-NP O
12.1 CD I-NP O
11.1-13.6 CD I-NP O
sec NN I-NP O
08/29/62 NN I-NP B-DATE
17 CD B-NP O
:26 CD I-NP O
PT-INR JJ B-NP O
1.0 CD I-NP O
08/29/62 CD I-NP B-DATE
17 CD I-NP O
:26 . O O
PTT NNP B-NP O
24.9 CD I-NP O
22.1-34.0 CD I-NP O
sec NN I-NP O
08/29/62 NN I-NP B-DATE
17 CD B-NP O
:26 CD I-NP O
Toxicology NN B-NP O
+ve NN B-NP O
for IN B-PP O
Ephedrine NNP B-NP O
. . O O
Hypercoagulation NNP B-NP O
Studies NNPS I-NP O
Act NNP B-NP O
Prot NNP I-NP O
C NNP I-NP O
Re NNP I-NP O
... : O O
2.5 CD B-NP O
>2.0 CD I-NP O
09/12/61 CD I-NP B-DATE
14:20 CD O O
Protein NNP B-NP O
S NNP I-NP O
( -LRB- I-NP O
Fu... NNP I-NP O
112 CD I-NP O
70-140 CD I-NP O
% NN I-NP O
09/12/61 CD I-NP B-DATE
14:20 CD O O
Protein NNP B-NP O
C NNP I-NP O
( -LRB- I-NP O
Fu... NNP I-NP O
160H CD I-NP O
70-140 CD I-NP O
% NN I-NP O
09/12/61 CD I-NP B-DATE
14:20 CD I-NP O
160( JJ B-ADJP O
H) NNP B-NP O
09/12/61 CD I-NP B-DATE
14:20 CD O O
Homocyst(e NNP B-NP O
)ine NN I-NP O
REFUSED VBN B-VP O
0-12 CD B-NP O
umol/L NNS I-NP O
09/12/61 IN B-PP B-DATE
06 CD B-NP O
:08 CD I-NP O
AT3 DT B-NP O
( -LRB- I-NP O
% NN I-NP O
NL NNP I-NP O
Act NNP I-NP O
... : O O
108 CD B-NP O
80-130 CD I-NP O
% NN I-NP O
09/12/61 CD I-NP B-DATE
14:20 CD O O
Interpretatio... NNP B-NP O
see VBP B-VP O
detail NN B-NP O
9/14/61 CD I-NP B-DATE
18:31 CD O O
Antiphospholipid NNP B-NP O
Antibodies NNPS I-NP O
Cardiolipin NNP B-NP O
A... NNP I-NP O
4.7 CD I-NP O
0-15 CD I-NP O
GPL NNP B-NP O
07/25/62 CD I-NP B-DATE
12:34 CD O O
Cardiolipin NNP B-NP O
A... NNP I-NP O
13.0 CD I-NP O
0-15 CD I-NP O
MPL NNP I-NP O
07/25/62 CD I-NP B-DATE
12:34 CD O O
EKG . O O
Sinus NNP B-NP O
Tachycardia NNP I-NP O
@ NNP I-NP O
110 CD I-NP O
, , O O
non-specific JJ B-NP O
anterior JJ I-NP O
ST NNS I-NP O
abnormalities NNS I-NP O
unchanged JJ B-ADJP O
from IN B-PP O
7/13/62 CD B-NP B-DATE
. . O O
Head NN B-NP O
CT NNP I-NP O
- : O O
No DT B-NP O
evidence NN I-NP O
of IN B-PP O
acute JJ B-NP O
intra-cranial JJ I-NP O
process NN I-NP O
MRI NNP B-NP O
- : O O
No DT B-NP O
acute JJ I-NP O
infarct NN I-NP O
on IN B-PP O
DWI NNP B-NP O
, , O O
pt NN B-NP O
did VBD B-VP O
not RB O O
complete JJ B-NP O
study NN I-NP O
. . O O
MRA NNP B-NP O
Pelvis NNP I-NP O
8/28/62 CD O B-DATE
1 LS O O
. . B-NP O
Patent NNP I-NP O
abdominal NN I-NP O
aorta NN I-NP O
and CC O O
visceral JJ B-NP O
vessels NNS I-NP O
as IN B-PP O
above JJ B-ADJP O
. . O O
2. DT B-NP O
Patent NNP I-NP O
aorto-iliac NN I-NP O
system NN I-NP O
3. CD B-NP O
On IN B-PP O
the DT B-NP O
right NN I-NP O
: : O O
Patent NNP B-NP O
arterial NN I-NP O
tree NN I-NP O
4 LS O O
. . B-NP O
On IN B-PP O
the DT B-NP O
left NN I-NP O
: : O O
Patent NNP B-NP O
arterial NN I-NP O
tree NN I-NP O
Renal NNP B-NP O
Ultrasound NNP I-NP O
Doppler NNP I-NP O
8/26/61 CD O B-DATE
NO DT B-NP O
EVIDENCE NN I-NP O
OF IN B-PP O
HYDRONEPHROSIS. NNP B-NP O
SLIGHTLY NNP I-NP O
ECHOGENIC NNP I-NP O
KIDNEYS. NNP I-NP O
TRACE NN I-NP O
FREE NN B-NP O
FLUID. . O O
A/P NNP B-NP O
: : O O
28 CD B-NP B-AGE
yo CD I-NP O
man NN I-NP O
with IN B-PP O
DM1 NNP B-NP O
, , O O
ESRD-HD NNP B-NP O
, , O O
HTN NNP B-NP O
, , O O
Hyperlipidemia NNP B-NP O
, , O O
thrombocytosis NN B-NP O
, , O O
here RB B-ADVP O
with IN B-PP O
hypertensive JJ B-NP O
emergency NN I-NP O
. . B-VP O
His PRP$ B-NP O
BP NNP I-NP O
has VBZ B-VP O
remained VBN I-VP O
high JJ B-ADJP O
, , O O
so RB O O
will MD B-VP O
attempt VB I-VP O
to TO I-VP O
reduce VB I-VP O
by IN B-PP O
25 CD B-NP O
% NN I-NP O
MAP NNP I-NP O
for IN B-PP O
a DT B-NP O
few JJ I-NP O
hours NNS I-NP O
and CC O O
then RB O O
start VB B-VP O
an DT B-NP O
oral JJ I-NP O
agent NN I-NP O
. . O O
Nitroprusside NN B-NP O
will MD B-VP O
be VB I-VP O
used VBN I-VP O
first JJ B-ADVP O
but CC O O
if IN B-SBAR O
he PRP B-NP O
needs VBZ B-VP O
an DT B-NP O
extended JJ I-NP O
treatment NN I-NP O
, , O O
will MD B-VP O
change VB I-VP O
to TO B-PP O
nicardipine JJ B-NP O
( -LRB- I-NP O
Bj NNP I-NP O
Q NNP I-NP O
Sugudoyta NNP I-NP O
1165 CD I-NP O
Glb NNP I-NP O
;7(9 CD I-NP O
Kk NNP B-NP O
1 CD I-NP O
) -RRB- I-NP O
:414-8 . O O
) -RRB- B-VP O
given VBN I-VP O
his PRP$ B-NP O
ESRD. NNP I-NP O
His PRP$ B-NP O
change NN I-NP O
in IN B-PP O
mental JJ B-NP O
status NN I-NP O
is VBZ B-VP O
likely RB B-ADJP O
due JJ I-ADJP O
to TO B-PP O
hypertensive JJ B-NP O
encephalopathy NN I-NP O
, , O O
but CC O O
it PRP B-NP O
is VBZ B-VP O
hard JJ B-ADJP O
to TO B-VP O
exclude VB I-VP O
other JJ B-NP O
sources NNS I-NP O
of IN B-PP O
end-organ NN B-NP O
involvement NN I-NP O
such JJ B-PP O
as IN I-PP O
the DT B-NP O
heart NN I-NP O
(especially RB B-VP O
considering VBG I-VP O
his PRP$ B-NP O
thrombocytosis NN I-NP O
) -RRB- B-VP O
given VBN I-VP O
his PRP$ B-NP O
ongoing JJ I-NP O
confusion NN I-NP O
. . O O
Other JJ B-NP O
sources NNS I-NP O
of IN B-PP O
his PRP$ B-NP O
confusion NN I-NP O
might MD B-VP O
include VB I-VP O
meningitis NNS B-NP O
given VBN B-PP O
his PRP$ B-NP O
leukocytosis NN I-NP O
. . O O
1 CD B-LST O
. . O O
CV '' O O
a DT B-NP O
. . I-NP O
Pump NNP I-NP O
i FW B-NP O
. . O O
Has VBZ B-VP O
an DT B-NP O
S3 NN I-NP O
, , O O
but CC O O
no DT B-NP O
signs NNS I-NP O
of IN B-PP O
L NNP B-NP O
or CC I-NP O
R NN I-NP O
heart NN I-NP O
failure NN I-NP O
. . O O
ii NNS B-NP O
. . O O
Will MD B-VP O
reduce VB I-VP O
afterload NN B-NP O
prog NN I-NP O
b NN B-NP O
. . O O
Rhythm NN O O
i FW O O
. . B-NP O
Sinus NNP I-NP O
tachycardia NN I-NP O
, , O O
will MD B-VP O
give VB I-VP O
IVFs NNP B-NP O
to TO B-VP O
reduce VB I-VP O
high-reninemic JJ B-NP O
natriuretic JJ I-NP O
state NN I-NP O
. . O O
c. NN B-NP O
Ischemia NNP I-NP O
i FW B-NP O
. . O O
No DT O O
EKG NN B-NP O
changes VBZ B-VP O
consistent JJ B-ADJP O
with IN B-PP O
ischemia NN B-NP O
, , O O
will MD B-VP O
cycle NN B-NP O
cardiac NN I-NP O
biomarkers NNS I-NP O
x NN I-NP O
3 CD B-NP O
, , O O
give VBP B-VP O
ASA NNP B-NP O
, , O O
Lipitor NNP B-NP O
. . O O
ii NNS B-NP O
. . O O
Will MD B-VP O
reduce VB I-VP O
afterload NN B-NP O
with IN B-PP O
Nitroprusside NNP B-NP O
, , O O
IVFs NNP B-NP O
, , O O
po NN B-NP O
anti-hypertensives NNS I-NP O
. . O O
2. . B-NP O
Neuro NNP I-NP O
a DT B-NP O
. . B-VP O
His PRP$ B-NP O
mental JJ I-NP O
status NN I-NP O
and CC I-NP O
leukocytosis NN I-NP O
are VBP B-VP O
likely JJ B-ADJP O
due JJ I-ADJP O
to TO B-PP O
hypertensive JJ B-NP O
encephalopathy NN I-NP O
but CC O O
potentially RB B-VP O
concerning VBG I-VP O
for IN B-PP O
possible JJ B-NP O
meningitis NN I-NP O
. . O O
Will MD B-VP O
perform VB I-VP O
lumbar JJ B-NP O
puncture NN I-NP O
, , O O
hold VBP B-VP O
Abx NNP B-NP O
since IN B-SBAR O
he PRP B-NP O
has VBZ B-VP O
been VBN I-VP O
in IN B-PP O
the DT B-NP O
hospital NN I-NP O
for IN B-PP O
more JJR B-NP O
than IN I-NP O
6h JJ I-NP O
, , O O
give VB B-VP O
if IN B-SBAR O
CSF NNP B-NP O
studies NNS I-NP O
indicate VBP B-VP O
it PRP B-NP O
. . O O
b NN B-NP O
. . B-VP O
Neuro NNP B-NP O
following VBG I-NP O
. . O O
3. . B-NP O
HTN NNP I-NP O
a DT B-NP O
. . O O
Will MD B-VP O
reduce VB I-VP O
MAP NNP B-NP O
by IN B-PP O
25 CD B-NP O
% NN I-NP O
to TO B-PP O
~100 CD B-NP O
, , O O
will MD B-VP O
start VB I-VP O
with IN B-PP O
Nitroprusside NNP B-NP O
, , O O
switch NN B-NP O
to TO B-PP O
Nicardipine NNP B-NP O
. . I-NP O
Will NNP I-NP O
re-start NNP I-NP O
some DT B-NP O
oral JJ I-NP O
agents NNS I-NP O
once RB B-ADVP O
reduced VBN B-VP O
. . O O
4 CD B-LST O
. . O O
DM1 '' O O
a DT B-NP O
. . I-NP O
Will NNP I-NP O
start NN I-NP O
half-dose NN I-NP O
of IN B-PP O
Insulin NNP B-NP O
NPH NNP I-NP O
, , O O
cover NN B-NP O
with IN B-PP O
RISS NNP B-NP O
5 CD B-NP O
. . O O
Renal NNP O O
a DT B-NP O
. . I-NP O
Will NNP I-NP O
need NN I-NP O
HD NNP I-NP O
, , O O
will MD B-VP O
consult VB I-VP O
Renal JJ B-ADJP O
. . O O
6 CD B-LST O
. . O O
Thrombocytosis '' O O
a DT B-NP O
. . I-NP O
Stable NNP I-NP O
, , O O
will MD B-VP O
consult VB I-VP O
Dr. NNP B-NP O
Morgan NNP I-NP B-DOCTOR
's POS B-NP O
team NN I-NP O
re NN I-NP O
: : O O
continuing VBG B-VP O
Hydroxyurea NNP B-NP O
. . O O
7. . B-NP O
Access NNP I-NP O
a DT B-NP O
. . I-NP O
L NNP I-NP O
arterial JJ I-NP O
line NN I-NP O
, , O O
peripheral JJ B-NP O
iv. NN I-NP O
8. . B-NP O
F/E/N NNP I-NP O
a DT B-NP O
. . I-NP O
IVFs NNP I-NP O
, , O O
will MD B-VP O
start VB I-VP O
oral JJ B-NP O
diet NN I-NP O
as IN B-PP O
mental JJ B-NP O
status NN I-NP O
improves VBZ B-VP O
. . O O
9 CD B-LST O
. . O O
Heme '' O O
a DT B-NP O
. . I-NP O
Has NNP I-NP O
baseline NN I-NP O
anemia NN I-NP O
, , O O
likely JJ B-NP O
currently RB B-VP O
hemoconcentrated VBN I-VP O
, , O O
will MD B-VP O
montor VB I-VP O
Hct NNP B-NP O
. . O O
10 CD B-NP O
. . O O
Prophylaxis NNP O O
a DT B-NP O
. . I-NP O
Senna NNP I-NP O
, , O O
Colace NNP B-NP O
, , O O
Nexium NNP B-NP O
, , O O
Heparin NNP B-NP O
. . O O
Name VB B-VP O
: : O O
Addison NNP B-NP B-DOCTOR
Keefe NNP I-NP I-DOCTOR
, , O O
MD NNP B-NP O
PhD NNP I-NP O
Pager NNP B-NP O
# # I-NP O
92783 CD O B-PHONE
PGY-2 . O O
